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6Medical University of Lodz, Lodz, PolandA B S T R A C TBackground: Nonadherence to antihypertensive medicines limits
their effectiveness, increases the risk of adverse health outcome,
and is associated with signiﬁcant health care costs. The multiple
causes of nonadherence differ both within and between patients and
are inﬂuenced by patients’ care settings. Objectives: The objective of
this article was to identify determinants of patient nonadherence to
antihypertensive medicines, drawing from psychosocial and eco-
nomic models of behavior. Methods: Outpatients with hypertension
from Austria, Belgium, England, Germany, Greece, Hungary, The
Netherlands, Poland, and Wales were recruited to a cross-sectional
online survey. Nonadherence to medicines was assessed using the
Morisky Medication Adherence Scale (primary outcome) and the
Medication Adherence Rating Scale. Associations with adherence
and nonadherence were tested for demographic, clinical, and psycho-
social factors. Results: A total of 2595 patients completed the ques-
tionnaire. The percentage of patients classed as nonadherent ranged
from 24% in The Netherlands to 70% in Hungary. Low age, low self-
efﬁcacy, and respondents’ perceptions of their illness and cost-ee front matter Copyright & 2015, International S
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ondence to: Dyfrig A. Hughes, Centre for Health Ec
d Road, Bangor, Wales LL57 2PZ, UK.related barriers were associated with nonadherence measured on
the Morisky Medication Adherence Scale across several countries. In
multilevel, multivariate analysis, low self-efﬁcacy (odds ratio ¼ 0.73;
95% conﬁdence interval 0.70–0.77) and a high number of perceived
barriers to taking medicines (odds ratio ¼ 1.70; 95% conﬁdence
interval 1.38–2.09) were the main signiﬁcant determinants of non-
adherence. Country differences explained 11% of the variance in
nonadherence. Conclusions: Among the variables measured,
patients’ adherence to antihypertensive medicines is inﬂuenced
primarily by their self-efﬁcacy, illness beliefs, and perceived barriers.
These should be targets for interventions for improving adherence,
as should an appreciation of differences among the countries in
which they are being delivered.
Keywords: adherence, behavioral economics, health psychology,
hypertension, self-efﬁcacy.
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Adherence to antihypertensive treatments is suboptimal [1], even
among patients participating in clinical studies, whose median
persistence with medicines is only about 1 year [2]. Patients who
are poorly adherent (proportion of days covered r40%) [3]
experience signiﬁcantly increased risk of acute cardiovascular
events, compared with those who adhere adequately (Z80%), and
incur greater health care costs [4]. The World Health Organization
[5] has called for further research to gain a better understanding
of the determinants of nonadherence to antihypertensive med-
icines, and to identify common risk factors for nonadherenceacross different countries, to inform strategies for improving
patient adherence.
Known determinants of nonadherence to antihypertensive
treatments may broadly be categorized as factors related to the
patients [6–9] and their familial and cultural context [10], con-
dition [11], treatment [8,11], socioeconomic characteristics, and
health professional/health care system [5,12]. Components of
sociocognitive and self-regulatory theory including attitude [13],
perceived behavioral control [13,14], low self-efﬁcacy [13,15,16],
lack of perceived treatment beneﬁts [11], perceived barriers [7,8],
illness perceptions [6,10], beliefs about medicines [6,11,17,18], and
lack of social support [10,19,20] are signiﬁcantly associated withociety for Pharmacoeconomics and Outcomes Research (ISPOR).
.K., and D.A.H. indicate that they have no competing interests to
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support the negative impact of the costs of medicines on adherence
[21], but there is a lack of empirical evidence on alternative
behavioral economic theories such as time preference. We are
unaware of any study in which a range of these factors has been
tested simultaneously to assess their combined contribution to
nonadherence across several countries.
The aim of this study, therefore, was to identify determinants
of patient nonadherence to antihypertensive medicines, drawing
from psychosocial and economic models of behavior, from a
cross-sectional survey across a number of European countries
with contrasting cultures, health care systems, and patient
characteristics.Methods
The research used an online, convenience cross-sectional sample of
adults with hypertension recruited from 11 European countries. We
tested the contribution of multiple, theory-driven determinants for
association with antihypertensive treatment nonadherence, and
reported our ﬁndings according to the STrengthening the Reporting
of OBservational studies in Epidemiology (STROBE) statement on
cross-sectional studies [22].
Procedure
After receipt of ethical approval from all relevant committees, we
invited ambulatory, adult patients with hypertension to participate
in an online questionnaire. Patients self-selected into this study in
response to advertisements placed in community pharmacies
(Austria, Belgium, England, France, Germany, Greece, The Nether-
lands, Portugal, Poland, and Wales) or hypertension clinics (Hun-
gary). Additional strategies were necessary to increase recruitment
in some countries. These included recruiting patients via general
practice surgeries (Poland and Hungary), placing advertisements in
the press (England and Wales), and using online patient support
groups (Poland). No incentive was offered for patients to participate.
The survey was administered anonymously through SurveyMon-
key, with one entry allowed per Internet Protocol address to reduce
the chance of multiple responses. Patient information sheets,
consent forms, and eligibility checks were provided online.
Inclusion Criteria
We included patients who consented, and who self-reported as
being 18 years or older, diagnosed by a doctor as having hyper-
tension that lasted at least 3 months, currently prescribed
antihypertensive medicine(s), and personally responsible for
administering their medicines.
Exclusion Criteria
Respondents who self-reported as being diagnosed with a “psy-
chiatric condition” or those living in a nursing home (or similar
facility) were excluded.
Potential Determinants
Potential determinants of nonadherence were identiﬁed from
published literature reviews [23,24]. The questionnaire was
developed from validated instruments, where available, and
covered participants’ demographic characteristics, use of medi-
cines, self-rated health [25], and a battery of scales derived from
economic [21] and sociocognitive [23,24] theories.
Affordability and cost-related behaviors were assessed by a
dichotomous question asking whether respondents had to think
about the money available to spend when obtaining their medicines
and six related items, each measured on a ﬁve-point Likert scale[26]. Components of the European Social Survey [27] assessed
household income: participants reported their main source of
income, their total annual income (in bands), whether they were
coping with their present income, and the ease or difﬁculty in
borrowing money when in need. We assessed participants’ time
preference for near versus distant enjoyment of health beneﬁts [28].
The internationally standardized European Task Force on Patient
Evaluations of General Practice (EUROPEP) measure [29] assessed
participants’ evaluations of the health care they receive.
Validated, self-report tools were used to assess personal and
sociocognitive determinants of nonadherence. Dispositional opti-
mism was measured using the Life Orientation Test on ﬁve-point
Likert scales [30]. Illness representations were measured using
the Brief Illness Perception Questionnaire [31], which assessed
personal beliefs about illness consequence, timeline, personal
control, treatment control, illness identity, concern about illness,
illness coherence, and emotional representations (the causal
subscale was removed because of translation issues). The Beliefs
about Medicines Questionnaire [32] assessed participants’ belief
in the necessity of their medicines and also concerns about their
medicines. Components of the theory of planned behavior [33,34]
measured attitudes/behaviors toward taking medicines, subjec-
tive norms of adherence, barriers to, and facilitators of, adher-
ence, intention to adhere, and self-efﬁcacy for adherence
behaviors, each scored on a ﬁve-point Likert scale. The Building
Research Initiative Group Illness Management and Adherence in
Transplantation (BRIGHT) questionnaire [35,36] was used to
assess constraints/facilitators of adherence using subscales for
barriers and social support.
Outcome Measures
The primary outcome measure was self-reported nonadherence,
based on the four-item Morisky Medication Adherence Scale [37].
This classiﬁed patients as being nonadherent according to a
single “yes” response to any of the four questions that made
speciﬁc reference to “high blood pressure medicine.” This vali-
dated scale is the most frequently used questionnaire measuring
adherence to medication [38]. An exploratory analysis was also
conducted of those categorized as intentionally nonadherent on
the basis of “yes” responses to two speciﬁc Morisky items that
identify nonadherence as a result of feeling better/worse. A
secondary outcome measure of adherence was provided by the
Medication Adherence Rating Scale (MARS) [39], which consisted
of ﬁve items rated on a Likert scale, with a low score (on a range
of 5–25) indicating lower levels of adherence. Our choice of
outcome measures was informed by the theoretical and empiri-
cal literature on medication adherence spanning the behavioral
and medical sciences from which the study questions emerged.
These two conceptually different measures provided dichoto-
mous data on nonadherence and continuous data on adherence
to patients’ antihypertensive medications.
The ﬁnal survey had a total of 135 items.
Translation
Measures that were not validated and available in the required
language were translated into the appropriate languages using
accredited translators who were native speakers of the target
languages and ﬂuent in English. Translations were checked for
compatibility with the original version in a process of back
translation, performed by persons who were native English
speakers and ﬂuent in each target language, to ensure that none
of the original meaning was lost. For each language, a third
individual acted as a reviewer and highlighted any discrepancies
between the forward and back translations, which were resolved
by discussion with the translators. All translations were
Table 1 – Demographic data and cross-country comparison.
Explanatory variable Country (no. of respondents) χ2 P value
Austria
(323)
Belgium
(180)
England
(323)
Germany
(274)
Greece
(289)
Hungary
(323)
The
Netherlands
(237)
Poland (323) Wales (323)
Age, mean
(95% CI) 60.2 (58.8–
61.5)
57.3 (55.6–
59.1)
59.6 (58.5–
60.7)
56.8 (55.4–
58.2)
63.9 (62.6–
65.2)
58.2 (56.8–
59.7)
58.3 (57.0–
59.5)
54.5 (53.2–
55.8)
61.1 (59.9–
62.2)
16.62 Po 0.001 df ¼ 8
Sex: female 145 (44.9) 64 (35.6) 141 (43.7) 154 (56.2) 173 (59.9) 179 (55.4) 115 (48.5) 171 (52.9) 119 (36.8) 64.54 Po 0.001 df ¼ 8
Education
Secondary only* 120 (37.2) 6 (3.3) 110 (34.1) 51 (18.6) 148 (51.2) 253 (78.3) 7 (3.0) 167 (51.7) 98 (30.3) 64.54 Po 0.001 df ¼ 8
Higher education 194 (60.1) 174 (96.7) 211 (65.3) 222 (81.0) 135 (46.7) 68 (21.1) 229 (96.6) 155 (48.0) 224 (69.3)
Marital status:
married
209 (64.7) 134 (74.4) 241 (74.6) 184 (67.2) 187 (64.7) 234 (72.4) 186 (78.5) 246 (76.2) 258 (79.9) 36.11 Po 0.001 df ¼ 8
Student/in
employment
119 (36.8) 98 (54.4) 166 (51.4) 150 (54.7) 119 (41.2) 124 (38.4) 151 (63.7) 169 (52.3) 143 (44.3) 70.47 Po 0.001 df ¼ 8
Health status
Poor 23 (7.1) 4 (2.2) 10 (3.1) 6 (2.2) 0 (0) 26 (8.0) 5 (2.1) 24 (7.4) 13 (4.0) 322.59 P o 0.001
df ¼ 24Fair 96 (29.7) 25 (13.9) 53 (16.4) 84 (30.7) 93 (32.2) 128 (39.6) 49 (20.7) 133 (41.2) 51 (15.8)
Good 128 (39.6) 77 (42.8) 123 (38.1) 140 (51.1) 140 (48.4) 132 (40.9) 112 (47.3) 138 (42.7) 116 (35.9)
Very good 74 (22.9) 72 (40.0) 137 (42.4) 44 (16.1) 55 (19.0) 36 (11.1) 69 (29.1) 28 (8.6) 142 (44.0)
Mean number of
medical
conditions
(95% CI) 2.84 (2.59–
3.08)
2.29 (2.10–
2.47)
2.28 (2.15–
2.42)
2.13 (1.97–
2.30)
2.85 (2.64–
3.06)
2.85 (2.68–
3.02)
2.08 (1.93–
2.24)
2.15 (2.02–
2.27)
2.42 (2.26–
2.57)
13.16 P o 0.001df ¼ 8
Mean number of
medicines
(95% CI) 4.43 (4.06–
4.79)
3.54 (3.19–
3.90)
3.84 (3.58–
4.10)
3.42 (3.14–
3.70)
4.37 (3.99–
4.75)
5.17 (4.80–
5.53)
3.44 (3.09–
3.79)
4.12 (3.83–
4.42)
3.80 (3.54–
4.06)
12.01 Po 0.001 df ¼ 8
Mean units of
medicines per day
(95% CI) 5.51 (4.95–
6.07)
3.78 (3.33–
4.23)
4.93 (4.45–
5.40)
3.92 (3.56–
4.27)
5.06 (4.57–
5.54)
7.44 (6.90–
7.98)
4.31 (3.45–
5.16)
3.20 (2.89–
3.51)
4.97 (4.45–
5.49)
22.41 Po 0.001 df ¼ 8
Most frequently
dosed medicine
Once daily 114 (35.3) 123 (68.3) 224 (9.3) 100 (36.5) 51 (17.6) 54 (16.7) 157 (66.2) 131 (40.6) 241 (74.6) 557.56 P o 0.001
df ¼ 16Twice daily 110 (34.1) 35 (19.4) 63 (19.5) 129 (47.1) 112 (38.8) 155 (48.0) 56 (23.6) 143 (44.3) 47 (14.6)
ZThrice daily 96 (29.7) 19 (10.6) 26 (8.0) 44 (16.1) 123 (42.6) 113 (35.0) 22 (9.3) 48 (14.9) 35 (10.8)
Note. Data are counts (%), unless otherwise indicated.
CI, conﬁdence interval.
* Secondary education meaning to secondary (high) school level.
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Fig. 1 – Percentage of complete responses according to country and item of the questionnaire. BIPQ, Brief Illness Perception
Questionnaire; BMQ, Beliefs about Medicines Questionnaire; BRIGHT, Building Research Initiative Group Illness Management
and Adherence in Transplantation; EUROPEP, European Task Force on Patient Evaluations of General Practice; LOTR, Life
Orientation Test Revised; MARS, Medication Adherence Rating Scale; TPB, theory of planned behavior.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 0 6 – 2 1 6 209coordinated by one project partner to ensure consistency. Piloting
in each country enabled identiﬁcation of any semantic
inconsistencies.Sample Size
Based on an expectation of 30% nonadherence [6] and a one-
sided 5% level of signiﬁcance, 323 completed Morisky scores were
required per country for within-country analyses.Data Analysis
Responses to the survey were coded in SPSS (version 19; IBM
Corporation, Armonk, NY) and analyzed in Stata (version 10;
StataCorp LP, College Station, TX). We assumed missing data to
be missing at random and imputed using multiple imputations
by chained equations [40], to create 25 data sets for each country.
For a single incomplete variable, multiple imputation constructs
a model relating the incomplete variable to variables in the
prediction model, and draws from the posterior predictive dis-
tribution of the missing data, conditional on the observed data.
Using multiple imputations by chained equations, imputed val-
ues were initialized by drawing at random from observed values.
Imputation of missing data was performed on variables ordered
by level of “missingness,” using observed and current imputed
values of all predictors. To ensure stability, this imputation step
was cycled 10 times for each of the 25 imputed data sets [41].
Analyses were performed on each set, and imputation-speciﬁc
coefﬁcients were pooled according to Rubin’s rules [42]. Imputed
data were used for all analyses with the exception of demo-
graphic variables for which data from complete cases were used.In the primary analysis, we calculated the percentage of
patients classed as nonadherent according to the Morisky score
in each country. Potential associations with nonadherence were
initially tested univariately using chi-square and independent
samples t tests (associations with the use of medicines were
adjusted for age), followed by a logistic regression with non-
adherence as the dependent variable. We applied a bivariate
method of selecting explanatory variables, whereby only varia-
bles found to be signiﬁcant (P o 0.05) in the univariate analysis
were entered into the regression model based on a theoretical
order [43,44], from determinants classiﬁed as demographic and
medicine use characteristics (distal) to attitudes and behaviors
(proximal). Assumptions regarding multicollinearity, singularity,
normality, linearity, and homoscedasticity were tested and met.
Country comparison analysis was conducted using chi-square
tests. We adopted a similar approach for the secondary outcome
of MARS adherence, but with a one-way analysis of variance to
test differences among countries.
To account for both within-country and between-country
variance, as a secondary analysis, two-level multilevel regression
models with respondents nested within country were speciﬁed
for both Morisky (logit model) total and intentional nonadher-
ence, and MARS adherence (linear regression model). Multilevel
models with random intercepts and ﬁxed effects were speciﬁed,
initially with all variables common to all countries. Noncontri-
butory variables were subsequently removed iteratively, deter-
mined by highest P value using backwards elimination (based on
P 4 0.05). We calculated the variance partition coefﬁcient [45] to
determine the attribution of country to the observed variance in
nonadherence.
A complete case analysis of Morisky total nonadherence was
performed to assess the sensitivity of our main ﬁndings to
Table 2 – Prevalence of self-reported total nonadherence and intentional nonadherence across European
countries based on Morisky responses, and adherence based on MARS.
Country Morisky MARS
Respondents self-reporting as
being nonadherent (as a
percentage of all respondents)
(95% CI)
Respondents self-reporting as
being intentionally
nonadherent (as a percentage
of nonadherers) (95% CI)
Mean score (95% CI)*
The Netherlands 24.1 (18.6–29.5) 21.1 (10.5–31.6) 23.86 (23.64–24.16)
Germany 33.2 (27.6–38.8) 35.2 (25.4–45.0) 23.47 (23.28–23.75)
Austria 33.7 (28.6–38.9) 51.4 (42.0–60.8) 23.25 (23.03–23.56)
Wales 38.1 (32.8–43.4) 25.2 (17.5–32.9) 23.46 (23.30–23.77)
Belgium 38.9 (31.8–46.0) 17.1 (8.3–26.0) 23.59 (23.50–23.99)
England 41.5 (36.1–46.9) 23.9 (16.7–31.1) 23.41 (23.17–23.65)
Greece 50.2 (44.4–55.9) 57.2 (49.2–65.3) 22.08 (21.71–22.48)
Poland 57.6 (52.2–63.0) 44.6 (37.5–51.8) 18.19 (17.77–19.01)
Hungary 70.3 (65.3–75.3) 18.1 (13.1–23.1) 22.88 (22.74–23.26)
Cross-country
comparison
χ2: 191.52 χ2: 108.87 ANOVA F test: 106.08–115.49†
(Complete case F: 103.24)
df: 8 df: 8
P ¼ 0.000 P ¼ 0.000 P ¼ 0.000
Tests cross-country difference in
self-reported nonadherence
Tests cross-country difference in
self-reported intentional
nonadherence, as a proportion of
all self-reported nonadherence
CI, conﬁdence interval; MARS, Medication Adherence Rating Scale.
* 95% CI of mean based on imputed data.
† Range of imputation-speciﬁc statistics.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 0 6 – 2 1 6210assumptions relating to missing data. In a post hoc analysis, we
assessed the impact of excluding Hungary from the analysis,
given that Hungary alone recruited patients from hypertension
clinics.Results
Participants
A total of 2630 adults from 11 countries completed the question-
naire. Target recruitment was achieved in ﬁve countries (Austria,
England, Hungary, Poland, and Wales). Study setup and initiation
was delayed in Belgium, Germany, Greece, and The Netherlands,
leading to nontarget recruitment. The analysis, therefore,
includes these countries that each recruited more than 100
participants (n ¼ 2595). There was an inadequate level of
available research support in France and Portugal that resulted
in low response (n ¼ 11 and n ¼ 33, respectively), and these were
excluded from the analysis. Included participants’ characteristics
are presented in Table 1. The overall level of missing data by
country ranged from 5% to 26%, with lowest rates seen on
demographic and clinical questions (0%–8%), MARS (o2%), med-
icine necessity and concerns (14%), and self-efﬁcacy (14%) and
highest rates seen on the income questions (22%), time prefer-
ence (22%), and BRIGHT barriers (23%) (Fig. 1).
There were signiﬁcant differences between country samples
on all demographic and clinical characteristics assessed. Self-
rated health was more often rated as poor or fair in Poland
(48.6%) and Hungary (47.6%) than in Belgium (16.1%), England
(19.5%), and Wales (19.8%). Fewer respondents from Hungary,
Greece, and Poland had received higher education than in other
countries. Respondents from Greece tended to be older and more
predominantly female, and together with Hungary and Austriahad the greatest number of comorbidities and were more likely to
be taking medicines more frequently than three times a day.
Prevalence of Nonadherence
Based on Morisky scores, it was found that nonadherence was
least prevalent in The Netherlands and most prevalent in
Hungary (Table 2). Intentional nonadherence was highest in
Greece. Polish respondents had signiﬁcantly lower levels of
adherence, as measured by MARS, than did respondents from
other countries.
Associations with Morisky Nonadherence and MARS
Adherence
Among demographic factors, only age showed associations
across several countries, with younger age associated with
Morisky nonadherence in Austria, Belgium, The Netherlands,
and Wales (Table 3) and older age associated with MARS adher-
ence in The Netherlands (Table 4). Unemployment was associ-
ated with nonadherence in England and Hungary only. None of
the medicine-related factors showed associations with nonad-
herence in more than one country. The perceived ease or
difﬁculty in borrowing money was associated with nonadherence
in England and Germany, and having available strategies to cope
with the costs of medicines was signiﬁcantly associated with
MARS-rated adherence in Belgium, England, Greece, and
Hungary.
No signiﬁcant associations were evident for optimism, but, in
contrast, beliefs about the illness did play a signiﬁcant role. Brief
Illness Perception Questionnaire factors of low perceived illness
consequences, low concern about illness, and low beliefs in
personal control over illness were signiﬁcantly associated with
nonadherence on the Morisky scale in Austria, Greece, Poland,
and Wales (Table 3), and high belief in treatment control, high
Table 3 – Summary of the logistic regression model using the Morisky nonadherence as the dependent variable*.
Explanatory
variable†
Country
Austria Belgium England Germany Greece Hungary The
Netherlands
Poland Wales
Demographic characteristics
Age 0.96 (0.93– 0.99)
P ¼ 0.012
0.97 (0.95– 1.00)
P ¼ 0.047
0.98 (0.94–
1.03) P ¼ 0.431
0.97 (0.94–
1.01) P ¼ 0.012
0.94 (0.91–0.98)
P ¼ 0.001
0.98 (0.94–
1.00) P ¼ 0.088
0.97 (0.93–1.00)
P ¼ 0.037
Employment 1.32 (0.56– 3.13)
P ¼ 0.521
3.14 (1.34–7.34)
P ¼ 0.008
1.25 (0.49–3.19)
P ¼ 0.646
2.93 (1.58–
5.42) P ¼ 0.001
1.12 (0.55–2.27)
P ¼ 0.762
0.82 (0.37–1.82)
P ¼ 0.618
Sociodemographic characteristics/clinical factors
Number of
tablets
0.97 (0.88–1.07)
P ¼ 0.502
0.88 (0.78–
0.98) P ¼ 0.025
Dosing frequency
Once daily 0.08 (0.03–0.26)
P o 0.001
Twice daily 0.24 (0.09–
0.62) P ¼ 0.004
Income source 0.72 (0.31– 1.67)
P ¼ 0.445
0.99 (0.36–
2.73) P ¼ 0.977
3.83 (1.31–
11.18) P ¼ 0.014
1.08 (0.45–2.58)
P ¼ 0.864
Borrowing income
Difﬁcult 6.26 (1.14–
34.46) P ¼ 0.035
3.01 (0.81–
11.12) P ¼ 0.098
1.30 (0.64–2.62)
P ¼ 0.469
Neither
difﬁcult nor
easy
5.28 (0.93–
30.17) P ¼ 0.061
1.82 (0.43–
7.72) P ¼ 0.418
3.36 (1.34–
8.43) P ¼ 0.010
Easy 5.47 (1.00–
29.77) P ¼ 0.050
3.08 (0.65–
14.59) P ¼ 0.157
0.59 (0.24–
1.47) P ¼ 0.261
Number of items
prescribed
1.06 (0.95–1.19)
P ¼ 0.313
0.86 (0.76–0.97)
P ¼ 0.017
0.84 (0.70–
1.00) P ¼ 0.051
Illness perceptions
Illness
consequences
0.89 (0.81– 0.99)
P ¼ 0.029
Personal control 0.94 (0.84– 1.04)
P ¼ 0.230
0.94 (0.83–
1.07) P ¼ 0.333
0.79 (0.66–
0.95) P ¼ 0.013
0.93 (0.82–1.06)
P ¼ 0.289
0.88 (0.79–
0.99) 0.031
Concern about
illness
0.79 (0.68–
0.92) P ¼ 0.002
Theory of planned behavior
Barrier 1.28 (1.03–
1.60) P ¼ 0.028
1.26 (0.97–1.63)
P ¼ 0.078
0.93 (0.72–1.22)
P ¼ 0.610
Self-efﬁcacy 0.79 (0.70– 0.90)
P o 0.001
0.82 (0.69–0.96)
P ¼ 0.016
0.62 (0.52–
0.74) P o 0.001
0.53 (0.43–
0.67) P o 0.001
0.82 (0.71–
0.95) P ¼ 0.006
0.84 (0.73–
0.96) P ¼ 0.013
0.81 (0.68–1.04)
P ¼ 0.111
0.70 (0.60–
0.82) P o 0.001
0.66 (0.56–0.79)
P o 0.001
BRIGHT
Barriers 1.04 (1.00–1.08)
P ¼ 0.035
1.04 (0.98–1.10)
P ¼ 0.155
1.05 (1.00–
1.10) P ¼ 0.061
1.05 (1.00–1.10)
P ¼ 0.051
1.06 (1.00–1.11)
P ¼ 0.034
1.05 (0.99–1.11)
P ¼ 0.107
Constant‡ 133.99 (6.92–
2593.41)
P ¼ 0.001
33.32 (4.06–
273.37) P ¼ 0.001
11.78 (0.17–
833.40)
P ¼ 0.256
649.33 (28.07–
15018.96)
P o 0.001
8.10 (0.36–
183.93)
P ¼ 0.189
4.13 (0.49–
35.10) P ¼ 0.194
33.71 (1.92–
591.49)
P ¼ 0.016
320.84 (9.36–
10993.92)
P ¼ 0.001
124.91 (1.44–
10848.02)
P ¼ 0.034
continued on next page
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 0 6 – 2 1 6212illness coherence, and high belief in personal control were
signiﬁcant in Austria, Greece, and Hungary based on MARS
assessment of adherence (Table 4). Illness identity, perceived
illness timeline, and emotional representations were not signiﬁ-
cant, neither were beliefs about medicines, in terms of their
necessity or concerns about taking them (Beliefs about Medicines
Questionnaire).
The sociocognitive variables, drawn mainly from the theory of
planned behavior, did not emerge consistently in the intercoun-
try analysis. Perceived barriers to adherence (whether changes to
daily routine makes taking medicines more difﬁcult) were related
to nonadherence only in Greece, although a high number of
barriers assessed by BRIGHT [35,36] were associated with non-
adherence in Austria and Poland. Intention to adhere was
associated with adherence in Hungary and Wales. Low self-
efﬁcacy, however, emerged signiﬁcant in relation to nonadher-
ence in all countries except The Netherlands, and high self-
efﬁcacy explained adherence in all countries except Poland.
Social support factors emerged signiﬁcant only in Hungary but
in a counterintuitive direction, in relation to low perceived
environmental support and greater adherence.
The variables examined in this study explained between
13.4% and 65.2% of the variability in MARS adherence (Table 4).
Multilevel Model
The multilevel logit model for Morisky nonadherence identiﬁed
males, being of younger age, being employed, low number of
medicines, high dosing frequency, high normative beliefs, low
self-efﬁcacy, high perceived barriers, low personal control, low
concern about illness, and difﬁculty in borrowing money as being
signiﬁcantly associated with nonadherence (Table 5). Associa-
tions were consistent in the model speciﬁed with Morisky inten-
tional nonadherence. Multilevel linear regression found that older
age, a lower level of education, a greater number of medicines,
less frequent dosing, having low perceived barriers, low percep-
tions of illness consequences, beliefs in treatment control, and
high self-efﬁcacy were connected to higher adherence as meas-
ured by MARS. Based on the Morisky scale, 11% and 7% of the
explained variance in total and intentional nonadherence,
respectively, was attributable to differences among countries
and 23% of the variance in adherence based on MARS was
attributable to differences among countries.
Sensitivity Analysis
The analysis of complete cases resulted in less precise estima-
tors, as expected, altering the signiﬁcance of some variables and
hence their inclusion in the ﬁnal model. Self-efﬁcacy and per-
ceived barriers (BRIGHT), however, remained signiﬁcant as in the
primary analysis.
When Hungary was excluded from the multilevel model
(because of the aforementioned difference in recruitment
method), we observed a reduction in between-country variance
in Morisky nonadherence (from 11% to 4%). Other factors
emerged as being signiﬁcant, including education, number of
medical conditions, attitudes, and intention to adhere, though
self-efﬁcacy and barriers remained signiﬁcant.Discussion
Self-reported nonadherence to antihypertensive medicines is
prevalent, even among the sampled population who were in
receipt of a current prescription for antihypertensive treatment.
Prevalence differs signiﬁcantly across countries, and although a
proportion of this variance is explained by country-level effects
and demographic characteristics, our principal ﬁnding is that
Table 4 – Summary of the ﬁnal regression model (all variables) using the MARS adherence-dependent variable: β coefﬁcient (95% CIs).
Explanatory
variable*
Country
Austria Belgium England Germany Greece Hungary The
Netherlands
Poland Wales
Demographic characteristics
Age 0.01 (0.02 to
0.03)
P ¼ 0.606
0.00 (0.02 to
0.03)
P ¼ 0.922
0.02 (0.01 to 0.05)
P ¼ 0.109
0.02 (0.01 to
0.04)
P ¼ 0.153
0.03 (0.00–
0.06) P ¼ 0.026
0.00 (0.02 to 0.03)
P ¼ 0.976
Sex 0.39 (0.10 to
0.88)
P ¼ 0.119
0.49 (0.00–0.98)
P ¼ 0.050
Sociodemographic/clinical factors
Cost-coping
strategies
0.10 (0.22
to 0.01)
P ¼ 0.076
0.17 (0.30
to 0.06)
P ¼ 0.004
0.12 (0.21 to 0.02)
P ¼ 0.020
0.06 (0.16
to 0.05)
P ¼ 0.319
0.35 (0.42 to
0.28)
P o 0.001
0.21 (0.28 to
0.15) P o 0.001
0.12 (0.25
to 0.02)
P ¼ 0.094
Time preference
Short 7.12 (2.14–
12.09) P ¼ 0.005
Illness perceptions
Personal control 0.01 (0.10 to 0.11)
P ¼ 0.931
0.11 (0.26 to
0.04) P ¼ 0.144
0.17 (0.04– 0.30)
P ¼ 0.011
0.11 (0.02 to
0.24) P ¼ 0.102
0.05 (0.24 to
0.33)
P ¼ 0.735
0.05 (0.05 to 0.15)
P ¼ 0.348
Treatment control 0.26 (0.13–
0.39)
P o 0.001
0.13 (0.02 to 0.28)
P ¼ 0.095
0.02 (0.17
to 0.13)
P ¼ 0.794
0.08 (0.08 to
0.24) P ¼ 0.299
0.09 (0.25 to
0.07) P ¼ 0.284
0.11 (0.27 to
0.50)
P ¼ 0.558
0.07 (0.08 to 0.20)
P ¼ 0.366
Illness coherence 0.07 (0.20 to 0.06)
P ¼ 0.274
0.17 (0.02– 0.32)
P ¼ 0.032
0.08 (0.06 to 0.21)
P ¼ 0.257
0.01 (0.13 to
0.10) P ¼ 0.814
Theory of planned behavior
Intention 0.09 (0.25
to 0.07)
P ¼ 0.286
0.06 (0.17 to 0.28)
P ¼ 0.623
0.15 (0.03 to
0.33) P ¼ 0.112
0.32 (0.09– 0.55)
P ¼ 0.007
0.01 (0.53
to 0.51)
P ¼ 0.971
0.33 (0.04–0.62)
P ¼ 0.028
Self-efﬁcacy 0.28 (0.16–
0.40)
P o 0.001
0.19 (0.02–
0.36)
P ¼ 0.027
0.30 (0.17–0.42)
P o 0.001
0.32 (0.19–
0.46)
P o 0.001
0.39 (0.26– 0.52)
P o 0.001
0.15 (0.03– 0.26)
P ¼ 0.016
0.25 (0.09–
0.41) P ¼ 0.002
0.29 (0.03 to
0.61)
P ¼ 0.072
0.37 (0.22–0.51)
P o 0.001
BRIGHT
Barriers 0.04 (0.07
to 0.00)
P ¼ 0.062
0.01 (0.05
to 0.03)
P ¼ 0.698
0.04 (0.09 to 0.01)
P ¼ 0.081
0.00 (0.03
to 0.03)
P ¼ 0.893
0.05 (0.09 to
0.01) P ¼ 0.010
0.07 (0.11 to
0.03) P ¼ 0.101
0.08 (0.17
to 0.00)
P ¼ 0.057
0.06 (0.11 to
0.00) P ¼ 0.060
Social support 0.02 (0.09
to 0.04)
P ¼ 0.520
0.00 (0.04 to 0.05)
P ¼ 0.920
0.05 (0.10 to
0.01) P ¼ 0.024
0.03 (0.02 to 0.07)
P ¼ 0.270
Constant 18.97 (15.83–
22.10)
P o 0.001
21.72 (19.04–
24.40)
P o 0.001
17.83 (13.96– 21.69)
P o 0.001
20.15 (17.35–
22.96)
P o 0.001
19.06 (16.32–
21.80) P o 0.001
19.76 (16.70– 22.82)
P o 0.001
19.48 (17.29–
21.68)
P o 0.001
13.74 (8.97–
18.51)
P o 0.001
19.37 (15.86– 22.88)
P o 0.001
Other predictors in
the model where
P 4 0.05†
2, 6, 11, 13,
14, 20, 22, 23
11, 14, 20 3, 8, 9, 10, 11, 13, 14,
15, 16, 17, 18, 19, 20,
22, 24
13, 14, 16, 17,
19, 20, 22
3, 5, 7, 8, 10, 11,
12, 14, 15, 17,
19, 24
1, 7, 10, 13, 14, 15,
16, 17, 19, 20, 22,
23, 24
24 13, 21, 23 3, 4, 5, 8, 11, 13, 14,
15, 16, 17, 19, 20,
23, 24
Adjusted R2 0.2831 0.2005 0.3809 0.2223 0.6521 0.4589 0.1335 0.1482 0.3570
BRIGHT, Building Research Initiative Group Illness Management and Adherence in Transplantation; MARS, Medication Adherence Rating Scale.
* Only coefﬁcients for predictors with P o 0.05 for at least one country are presented.
† Marital status (1), employment (2), dosage frequency (3), number of medicines (4), number of medical conditions (5), income source (6), total income (7), income perception (8), borrowing (9),
affordability problem (10), health status (11), time preference: long (12), satisfaction with practitioner (13), satisfaction with practice (14), optimism (15), illness consequences (16), identity (17),
concern about illness (18), emotional representations (19), concern about medicine (20), necessity of medicine (21), attitude (22), normative beliefs (23), barriers—theory of planned behavior (24).
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Table 5 – Summary of multilevel regression models for Morisky and MARS as outcome measures.
Explanatory variable Morisky MARS
Odds ratio 95% CI β coefﬁcient 95% CI
Sex 1.22* 1.01–1.47
Age 0.98† 0.97–0.99 0.01* 0.00–0.02
Employment 0.74* 0.59–0.94
Education 0.34‡ 0.60 to 0.09
Number of medicines 0.89† 0.86–0.93 0.06* 0.01–0.10
Dosing frequency 1.30‡ 1.12–1.52 0.24‡ 0.42 to 0.06
Normative beliefs 1.05* 1.01–1.09
Self-efﬁcacy 0.73† 0.70–0.77 0.36† 0.30–0.42
Barriers (BRIGHT) 1.70† 1.38–2.09 0.83† 1.10 to 0.57
Illness consequences 0.06* 0.10 to 0.01
Personal control 0.94‡ 0.90–0.97
Treatment control 0.11‡ 0.04–0.19
Concern about illness 0.94‡ 0.91–0.98
Borrowing money 0.85‡ 0.78–0.94
Constant 34.59† 13.5–88.5 19.45† 18.1–20.8
Random effects parameters Variance 95% CI Variance 95% CI
Between-country variance (σu
2) 0.40 0.15–1.07 2.14 0.79–5.80
Within-country variance (σe
2) 7.09 6.63–7.57
% variance attributable to differences between countries 10.82 4.35–24.49 23.20 10.63–43.40
Notes. For the logit model, σe
2 ¼ π2/3.
Variance partition coefﬁcient ¼ σu2/( σu2 þ σe2).
Full model speciﬁcation: age, sex, education, marital status, employment, number of medical conditions, number of different medicines,
number of tablets, dosing frequency, number of items prescribed, health status, affordability problem, optimism, necessities, concerns about
medicine, attitudes, normative beliefs, barrier (theory of planned behavior), facilitators, intention, self-efﬁcacy, prescriber of medicines, sex of
prescriber, satisfaction with practitioner, satisfaction with practice, barriers (averaged as one less collected in Wales), social support, illness
consequences, illness timeline, personal control, treatment control, illness symptomaticity, concern about illness, illness coherence,
emotional representations, income source, income perception, ease of borrowing, total income.
BRIGHT, Building Research Initiative Group Illness Management and Adherence in Transplantation; CI, conﬁdence interval; MARS, Medication
Adherence Rating Scale.
* P o 0.05.
† P o 0.001.
‡ P o 0.01.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 0 6 – 2 1 6214potentially modiﬁable factors of low perceived self-efﬁcacy and,
to a lesser extent, low personal control beliefs and high perceived
barriers are consistently associated with nonadherence. Per-
ceived barriers to adherence included forgetfulness or interrup-
tion of daily routine, practical difﬁculties, and feeling
overwhelmed by circumstances or complexity of regimen. Our
ﬁnding of common associations with nonadherence across differ-
ent countries supports the importance of these factors, partic-
ularly given the signiﬁcant differences that exist in cultural,
medical practices, and health care systems that contribute to a
small proportion of the variance in nonadherence.
Adherence is generally explained by the converse of the
above, but cost-related behavior (i.e., strategies to cope with the
cost of prescriptions) and intention also emerged as signiﬁcant in
several countries. The multilevel analysis of all countries shows
that although many factors act in the opposite direction depend-
ing on whether we are addressing nonadherence or adherence,
some uniquely explain nonadherence, for example, employment
status, low normative beliefs, low personal control, low illness
concern, and low borrowing potential, and others uniquely
explain adherence, for example, lower education, low perceived
illness consequences (both these are counterintuitive), and
beliefs in treatment control. The multilevel analyses also suggest
that where possible, a reduction in dose frequency and number of
prescribed medicines might achieve improvements in adherence.The literature on adherence to medicines contains many
analyses that have tested the signiﬁcance of clinical, treatment,
and demographic characteristics as predictors of nonadherence,
assuming that behavior is a function of these characteristics
alone. This approach has signiﬁcant limitations. Our analysis is
rooted in behavioral theories to reﬂect the notion that individual
beliefs and social inﬂuences are potentially more relevant deter-
minants of intentional and nonintentional nonadherence (and of
adherence) than relatively ﬁxed attributes of the person or the
clinical situation. Previous studies have shown that, based on
sociocognitive and self-regulation theories, personal and per-
ceived control [6,10,13,15,16], perceived beneﬁts of treatment
[7,11], and perceived barriers—such as forgetfulness and experi-
enced or anticipated adverse effects [7,8]—are signiﬁcant predic-
tors of nonadherence in patients taking antihypertensive
medicines. Associations between higher levels of self-efﬁcacy
and adherence in patients with hypertension have been noted
previously [13,46].
The novelty and key strength of our study is that a range of
theoretically informed factors derived from behavioral theories
in health psychology and economics were tested concurrently
across several European countries. Our analysis also considered
the distinction between intentional and unintentional nonad-
herence. Associations with intentional nonadherence were
fewer, and although several overlapped with those associated
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 0 6 – 2 1 6 215with overall nonadherence, that is, age, self-efﬁcacy, and per-
ceived barriers, other factors included the number of medical
conditions, concerns about medicines, perceived illness identity,
and behavioral intention. The act of deliberately choosing to
avoid taking medicines, therefore, warrants interventions that
more explicitly target illness and treatment and behavioral
beliefs.
There are several caveats to our analysis, however, which may
limit the strength of the interpretations. First, only 5 of the
intended 11 countries reached target recruitment. We pragmati-
cally included all nine countries that recruited an appreciable
number of patients; however, this reduced the precision of the
estimates of nonadherence in each country and limited the
strength of inferences. Second, our analyses might be con-
founded by differences in methods of recruitment. Although all
countries—except Hungary—recruited via community pharma-
cies, the exclusion of Hungary from the secondary analysis
resulted in more variables being signiﬁcant. The main ﬁndings
of the primary (per country) analysis, however, remained
unchanged. Third, because responses were elicited via self-
administered questionnaires, we had no means of conﬁrming
hypertension diagnosis, nor other responses, or mitigate any self-
presentation bias, which would reduce the external validity of
our ﬁndings. Fourth, we were unable to assess the impact of
nonresponse bias [47] because those who failed to complete the
outcome measures—which were at the beginning of the ques-
tionnaire—were not allowed to progress through the remainder
of the survey. The length of the survey represents a ﬁfth
limitation, which may have had an impact on completion rates.
The variables ultimately emerging as being associated with non-
adherence and adherence (i.e., theory of planned behavior bar-
riers and self-efﬁcacy), however, had relatively low levels of
missingness and we improved precision by performing multiple
imputation. Although multiple imputation addresses problems in
complete case analyses related to loss of efﬁciency and bias due
to differences between observed and unobserved data, it is no
substitute for a complete data set and requires an important but
unveriﬁable assumption that data are missing at random. More-
over, only subscale totals rather than every individual item were
imputed for health psychology measures. This may introduce
bias because data from respondents who completed some, but
not all, of the items in a subscale were discarded. Sixth, although
we used validated scales wherever possible, full testing of the
BRIGHT measure did not exist at the time of the study. Finally,
self-reported measures of adherence are prone to bias [38], and
may not distinguish among failure to initiate dosing, incorrect
implementation of the dosing regimen, and treatment discontin-
uation [48]. In mitigation, however, we used two measures of
adherence and both had a signiﬁcant association with self-
efﬁcacy.
Notwithstanding these limitations, the ﬁndings can inform
the development of nonadherence-reducing (or adherence-
enhancing) interventions. Most importantly, the common varia-
bles identiﬁed within our study are amenable to change through
improved communication with health care professionals or brief
cognitive-behavioral intervention. Reviews of adherence-
improving interventions [49,50] offer support for self-efﬁcacy
enhancement, with modest effects reported in trials of suppor-
tive and individually tailored telephone calls, information on self-
management, checks on understanding, and concerns regarding
medicines and empowerment. Our analysis suggests that a
theoretically informed, controlled trial of cognitive-behavioral
interventions, focused on increasing self-efﬁcacy and related
control beliefs and reducing perceived barriers to adherence
behaviors, is warranted. Given the broad spectrum of potential
barriers and the observation of independent, country-level differ-
ences, which may be related to cultural, health service, or otherfactors, interventions that are tailored speciﬁcally to the popula-
tion in which they are being delivered are the most likely to be
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